Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Six Month Randomized Controlled Dietary Intervention Study of the New Nordic Diet vs Average Danish Diet in Adults (18-65y) Using the Shop Model for Optimal Dietary Adherence
Brief Summary: The objective is to investigate whether New Nordic Diet (NND) versus Average Danish Diet (ADD) in adults (18-65 y) with central obesity and components of the metabolic syndrome can improve body weight loss and risk markers of the metabolic syndrome, type 2 diabetes and cardiovascular diseases.


Options:
A: Inclusion Criteria:

* impaired glucose tolerance (oral glucose tolerance test with 2-h glucose concentration 7,8-11,0 mmol/l) OR
* impaired fasting glucose fasting plasma glucose concentration 5,6-6,9 mmol/l = IFG)
* and two of the criteria for metabolic syndrome:
* BMI 26-39 kg/m2
* Waist circumference \> 102 cm (men) or \> 88 cm (women)
* hypertriglyceridemia (fasting serum triglyceride conc \> 1,7 mmol/l),
* HDL-cholesterol (fasting serum HDL conc \< 1,0 mmol/l for men and \< 1,3 mmol/l for women)
* Blood pressure ≥ 130/≥ 85 mmHg

Exclusion Criteria:

* BMI \> 40 kg/m2
* fasting serum triglyceride conc \> 3.5 mmol/l
* fasting serum cholesterol \> 8 mmol/l
* type 1 or 2 diabetes
* abnormal liver, kidney or thyroid function
* large alcohol intake (women \>16, men \> 24 doses (4cl liquor or equivalent) during week)
* inflammatory bowel disease
* disease that prevents participation
* neuroleptic neuroleptic cortisone medication
B: Inclusion Criteria:

1. Baseline SBP 130-159 mmHg (+/- 2mmHg) or DBP 85-99 mmHg (+/- 2 mm Hg)
2. Age 35 years or older
3. BMI 25.0-39.99 kg/m², with a maximum weight of 300 lbs
4. Willing and able to participate fully in all aspects of the intervention
5. Must currently be sedentary (less than 3x/wk for 30 mins each time)
6. Informed consent

Exclusion Criteria:

1. Use of weight-loss medication and/or participation in a structured weight- loss program in the 3 months prior to 1st screening visit.
2. Regular use of an anti-hypertensive drug or other drugs that raise or lower BP and if discontinued use, must be off for 1 month before screening
3. Current use of insulin or oral hypoglycemic agents
4. Current use of medications for treatment of psychosis or manic-depressive illness.
5. ADHD medications (Ritalin/Aderol/amphetamines
6. Cardiovascular Event
7. Coronary Artery Disease
8. Congestive Heart Failure
9. Current symptoms of Angina for peripheral vascular disease
10. Cancer diagnosis (except for non-melanoma skin cancer) or treatment in past 2 years
11. Fasting blood sugar \>126 mg/dl
12. Gastric Bypass/Bariatric Surgery
13. Pyschiatric hospitalization in the past 2 years.
14. Unable or willing to consume all of the dietary foods provided during the 2-week feeding.
15. Consumption of more than 21 alcoholic drinks per week or binge drinking
16. Alcoholism as determined by the Alcohol AUDIT (screening questionnaires)
17. Planning to leave the area prior to the anticipated end of participation
18. Body weight change of \>15lbs in the 3 months prior to the 1st screening visit
19. Pregnant, breast feeding, or planning pregnancy prior to end of participation
20. Current participation in another clinical trial until after completion of T2
21. Investigator discretion for safety or adherence reasons
22. Controlled substance abuse
C: Inclusion Criteria:

* abdominal obesity

Exclusion Criteria:

* BMI \> 45, previous weight change
D: Inclusion Criteria:

* Informed Consent
* Clinical: Unstable coronary disease with documented vessel/myocardial damage

  * Acute Myocardial Infarction
  * Revascularization

Exclusion Criteria:

* Age \< 20 or \> 75 years (or life expectancy lower than 5 years).
* Patients already planned for revascularization.
* Patients submitted to revascularization in the last 6 months
* Grade II-IV Heart failure.
* Left ventricle dysfunction with ejection fraction lower than 35%.
* Patients unable to follow a protocol.
* Patients with severe uncontrol of Diabetes Mellitus, or those with Renal Insufficiency with plasma creatinine higher than 2mg/dl, or cerebral complications of Diabetes mellitus.
* Other chronic diseases:

  * Psychiatric diseases
  * Renal Insufficiency
  * Chronic Hepatopathy
  * Active Malignancy
  * Chronic obstructive pulmonary disease
  * Diseases of the digestive tract Endocrine disorders
* Patients participating in other Clinical trials (in the enrollment moment or 30 days prior).

Answer: C